<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023776</url>
  </required_header>
  <id_info>
    <org_study_id>URMC 09-006</org_study_id>
    <nct_id>NCT01023776</nct_id>
  </id_info>
  <brief_title>Infectivity, Replication &amp; Immunogenicity of Live nH1N1 Vaccine</brief_title>
  <official_title>Evaluation of the Infectivity, Replication, and Immunogenicity of Live, Attenuated A/California/07/09 (nH1N1) Influenza Vaccine in Serosusceptible Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the amount of live virus that can be recovered from
      the nose of people who are vaccinated with the licensed live vaccine against H1N1, and to
      describe the immune response to vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By looking at the immune response before and after vaccine, we hope to understand the factors
      that determine the immune response and detailed shedding patterns of live novel H1N1 vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Shed Virus</measure>
    <time_frame>28 days post vaccine 1 and 28 days vaccine 2</time_frame>
    <description>number of participants who shed virus above the limit of detection at any timepoint after vaccine. The limit of detection is 0.5 tissue culture infectious doses per mL of nasal wash.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Difference Between Cycle Time and Detection Threshold</measure>
    <time_frame>day 10 post vaccine 1</time_frame>
    <description>The mean difference was calculated by real-time polymerase chain reaction (PCR) on nasal wash samples. Cycle time is the cycle number at which the PCR reaction is positive with a range of 0-40 cycles. The detection threshold is 40 cycles.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>live monovalent H1N1 vaccine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A/California/07/09 live monovalent H1N1 vaccine 0.2 given intranasally, 2 doses given 28 days apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/California/07/09 live monovalent H1N1 vaccine</intervention_name>
    <description>0.1mL per nares intranasally, second identical dose given 28 days after first vaccine</description>
    <arm_group_label>live monovalent H1N1 vaccine</arm_group_label>
    <other_name>Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-32 years, inclusive

          -  No history of Novel H1N1 virus or vaccine

          -  Female not able to bear children or not pregnant and agrees to practice effective
             birth control

          -  Female negative pregnancy test

          -  Good Health

          -  Ability to understand and comply with protocol

          -  Provided Informed Consent

        Exclusion Criteria:

          -  Previous history of vaccination against novel H1N1 or laboratory documented H1N1
             infection

          -  History of egg allergy or is allergic to other components of the vaccine

          -  A women who is pregnant or breastfeeding or intends to get pregnant during the study
             period between enrollment and 30 days following vaccination

          -  Subject is immunosuppressed as the result of underlying illness or treatment with
             immunosuppressive or cytotoxic drugs or use of chemotherapy or radiation therapy in
             the preceding 36 months

          -  Subject has active neoplastic disease (excluding non-melanoma skin cancer or prostate
             cancer that is stable in the absence of therapy) or a history of any hematological
             malignancy. &quot;active is defined as treatment within the past 5 years

          -  Long term (greater than 2 weeks) use of oral or parental steroids, or high- dose
             inhaled steroids (&gt;800 mcg/day of beclomethasone dipropionate or equivalent) within
             the preceding 6 months (nasal and topical steroids allowed)

          -  Received immunoglobulin or another blood product within 3 months prior to enrollment
             in this study

          -  Subject has received an inactivated vaccine within 2 weeks or a live vaccine within 4
             weeks prior to enrollment in this study or plans to receive another vaccine within the
             next 28 days (or 56 days for the vaccine naive recipients)

          -  Subject has an acute or chronic medical condition that, in the opinion of the
             investigator, would render vaccination unsafe or would interfere with the evaluation
             of responses. Those conditions include chronic conditions recognized as risk factors
             for influenza complications or as contraindicated for live vaccination, including
             chronic cardiac (exclusive of hypertension) or pulmonary conditions (including
             asthma), diabetes mellitus, or renal impairment

          -  Subject has an acute illness or an oral temperature greater then 99.9 degrees F(37.7
             C)within 3 days prior to enrollment or vaccination. Subject who has acute illness that
             was treated, symptoms resolved are eligible to enroll as long as treatment is complete
             and symptoms resolved &gt; 3 dyas prior to enrollment.

          -  Subject is currently participating or plans to participate in a study that involves an
             experimental agent (vaccine, drug, biologic, device, blood product, or medication) or
             has received an experimental agent within 1 month prior to enrollment in this study,
             or intends to donate blood during this period.

          -  Subject has any condition that would, in the opinion of the site investigator, place
             the subject at an unacceptable risk of injury or render the subject unable to meet the
             requirements of the protocol

          -  Subject has a history of alcohol or drug abuse in the 5 years prior to enrollment.

          -  Subject has known human immunodeficiency virus, hepatitis B, or hepatitis C infection.

          -  Subject has a previous history of Guillain-Barre syndrome within 6 weeks of receipt of
             influenza vaccine

          -  Subject has any condition that the principal investigator (PI) believes may interfere
             with the successful completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>32 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John J. Treanor, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vaccine Research Unit Room 3-5000</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <results_first_submitted>August 2, 2011</results_first_submitted>
  <results_first_submitted_qc>November 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2015</results_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>John Treanor</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Swine Flu</keyword>
  <keyword>H1N1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy Volunteers were recruited from the general public between December 2009 and January 2010</recruitment_details>
      <pre_assignment_details>28 volunteers were recruited; 20 were enrolled and received at least 1 dose of vaccine, 8 were excluded (2 refused further participation and 6 did not meet inclusion criteria #2)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Live Monovalent H1N1 Vaccine</title>
          <description>Subjects received 2 doses of vaccine 0.1 ml in each nostril intranasally 28 days apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20">Subjects received 2 dose of vaccine 0.1 ml in each nostril intra nasally 28 days apart</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Live Monovalent H1N1 Vaccine</title>
          <description>Live Monovalent H1N1 vaccine 0.1 ml in each nostril times 2 doses given intranasally 28 days apart</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Shed Virus</title>
        <description>number of participants who shed virus above the limit of detection at any timepoint after vaccine. The limit of detection is 0.5 tissue culture infectious doses per mL of nasal wash.</description>
        <time_frame>28 days post vaccine 1 and 28 days vaccine 2</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Live Monovalent H1N1 Vaccine</title>
            <description>Live Monovalent H1N1 vaccine 0.1 ml in each nostril times 2 doses given intranasally 28 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Shed Virus</title>
          <description>number of participants who shed virus above the limit of detection at any timepoint after vaccine. The limit of detection is 0.5 tissue culture infectious doses per mL of nasal wash.</description>
          <population>per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Difference Between Cycle Time and Detection Threshold</title>
        <description>The mean difference was calculated by real-time polymerase chain reaction (PCR) on nasal wash samples. Cycle time is the cycle number at which the PCR reaction is positive with a range of 0-40 cycles. The detection threshold is 40 cycles.</description>
        <time_frame>day 10 post vaccine 1</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Live Monovalent H1N1 Vaccine</title>
            <description>Live Monovalent H1N1 vaccine 0.1 ml in each nostril times 2 doses given intranasally 28 days apart</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Difference Between Cycle Time and Detection Threshold</title>
          <description>The mean difference was calculated by real-time polymerase chain reaction (PCR) on nasal wash samples. Cycle time is the cycle number at which the PCR reaction is positive with a range of 0-40 cycles. The detection threshold is 40 cycles.</description>
          <population>per protocol</population>
          <units>cycles</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0075" lower_limit=".001" upper_limit=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>56 days</time_frame>
      <desc>Participants were queried at each visit about the occurence of any adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Live Monovalent H1N1 Vaccine</title>
          <description>Live Monovalent H1N1 vaccine 0.1 ml in each nostril times 2 doses given intranasally 28 days apart</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Swollen glands</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Light Headed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstral Cramps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nosebleed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Runny nose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stuffy nose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Treanor&lt; M.D.</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-275-5871</phone>
      <email>john_treanor@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

